SCHEMBL2636552

SCHEMBL2636552

CN(c1ccccc1Cl)C1CCN(C(=O)CN)CC1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 1/20 0.42
ALDH1A1 P00352 3/20 0.41
EPHX2 P34913 1/20 0.40
SMN1; SMN2 Q16637 4/20 0.39
LMNA P02545 1/20 0.39
KMT2A Q03164 1/20 0.39
OPRD1 P41143 1/20 0.39
CDYL Q9Y232 1/20 0.39
CDY1; CDY1B Q9Y6F8 1/20 0.39
UTS2R Q9UKP6 1/20 0.39
KDM1A O60341 2/20 0.38
MAOA P21397 2/20 0.38
MAOB P27338 2/20 0.38
RAB9A P51151 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
SIGMAR1 Q99720 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL3 Q96JM7 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2636041 0.85 SMN1; SMN2 (0.39) ALDH1A1SMN1; SMN2LMNAKMT2AOPRD1
SCHEMBL27833476 0.84 OPRM1 (0.46) OPRM1ALDH1A1SMN1; SMN2LMNAKMT2A
SCHEMBL2636549 0.83 OPRM1 (0.41) OPRM1ALDH1A1SMN1; SMN2LMNAKMT2A
SCHEMBL2636976 0.82 RBP4 (0.47) ALDH1A1SMN1; SMN2LMNAKMT2ACDYL
SCHEMBL70517 0.78 SMN1; SMN2 (0.54) ALDH1A1SMN1; SMN2LMNAKMT2ARAB9A
SCHEMBL69765 0.78 MEN1 (0.55) KMT2A
SCHEMBL2636880 0.74 ALDH1A1 (0.48) ALDH1A1EPHX2SMN1; SMN2LMNAKMT2A
SCHEMBL19702324 0.72 L3MBTL1 (0.46) ALDH1A1SMN1; SMN2KMT2ARAB9AL3MBTL1
SCHEMBL15808501 0.72 L3MBTL3 (0.51) ALDH1A1CDYLCDY1; CDY1BKDM1AMAOA
SCHEMBL4562378 0.72 RAB9A (0.40) ALDH1A1EPHX2SMN1; SMN2KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129376-B2 Piperidine derivatives as inhibitors of stearoyl-CoA desaturase AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2012-03-06 US claimed
US-20090239810-A1 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2009-09-24 US claimed
US-10973810-B2 Methods for the treatment of neurological disorders YUMANITY THERAPEUTICS, INC. (US) 2021-04-13 US disclosed
EP-3566055-A1 METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS Yumanity Therapeutics, Inc. (US) 2019-11-13 EP disclosed
WO-2018129403-A1 METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS YUMANITY THERAPEUTICS (US) 2018-07-12 WO disclosed
US-20180193325-A1 METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS JANSSEN PHARMACEUTICA NV (BE) 2018-07-12 US disclosed
US-8129376-B2 Piperidine derivatives as inhibitors of stearoyl-CoA desaturase AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2012-03-06 US disclosed
US-20090239810-A1 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10973810-B2 Methods for the treatment of neurological disorders NLN, CLN6, OTC OPRM1 2452/4885ALDH1A1 934/4885EPHX2 1185/4885
US-20090239810-A1 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE SCD, SCD5, FADS2 OPRM1 3623/4885ALDH1A1 784/4885EPHX2 1023/4885
US-20180193325-A1 METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS NLN, CLN6, OTC OPRM1 2452/4885ALDH1A1 934/4885EPHX2 1185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.